


Compound 23 | IL-17A

oral interleukin 17A modulator
favorable in vivo PK profile in multiple species
from a previous patent and SBDD

J. Med. Chem.

LEO Pharma Research & Early Development,
Ballerup, DK




BMS-986120 | PAR4

oral PAR4 antagonist
Ph. II completed in thrombosis (discontinued)
HTS, potency, and PK opt.

J. Med. Chem.

Bristol-Myers Squibb, Princeton, NJ




EZM0414 | SETD2

oral SETD2 Inhibitor
Ph. I candidate in oncology
in-house library screening and SBDD

ACS Med. Chem. Lett.

Epizyme Inc., Cambridge, MA




DNL201 | LRRK2

oral LRRK2 kinase inhibitor
Ph. I completed in Parkinson's Disease
HTS, SBDD, and CNS-focused opt.

Sci. Transl. Med.

Denali Therapeutics Inc., South San Francisco, CA




Iclepertin | GlyT1

oral GlyT1 inhibitor
Ph. III candidate in schizophrenia
10 and 25 mg PO QD efficacy in CIAS improv.

J. Pharmacol. Exp. Ther.

Boehringer Ingelheim Pharma, Biberach
an der Riss, DE




BMS-986339 | FXR

oral nonbile acid FXR agonist
FGF15 induction in a BDL mouse model
SBDD

J. Med. Chem.

Biocon-Bristol Myers Squibb Research
and Development Center, Bangalore, IN




MK-0159 | CD38

oral CD38 inhibitor
in vivo efficacy in a murine model of cardiac I/R
from the previously disclosed inhibitor CD38i

J. Med. Chem.

Mitobridge (an Astellas Company), Cambridge, MA




TAS1553 | RNR

oral RNR subunit interaction inhibitor
Ph. I candidate in oncology
HTS and SBDD

Commun. Biol.

Taiho Pharmaceutical Co., Ltd., Tsukuba, JP




NTQ1062 | Akt

oral Akt inhibitor
Ph. I in advanced solid tumors
scaffold hopping and PK opt.

J. Med. Chem.

Nanjing Chia-Tai Tianqing Pharmaceutical Co.,
Ltd., Nanjing, CN



Apararenone | MR

oral nonsteroidal MR antagonist
Ph. II candidate in DN and NASH (discontinued)
previous literature and hypothesis-driven opt.

J. Med. Chem.

Mitsubishi Tanabe Pharma Corporation,
Yokohama, JP